http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
유아혈관종 환아 375명에서 두 가지 제형의 경구 프로프라놀롤 치료 효과와 안전성에 대한 한국 단일기관에서의 경험
이현지 ( Hyun Ji Lee ),하기웅 ( Giung Ha ),정호윤 ( Ho Yun Chung ),이종민 ( Jong Min Lee ),이상엽 ( Sang Yub Lee ),허승 ( Seung Huh ),김지윤 ( Ji Yoon Kim ),이석종 ( Seok-jong Lee ) 대한피부과학회 2021 대한피부과학회지 Vol.59 No.3
Background: Oral propranolol has recently been introduced as a successful treatment for infantile hemangioma (IH). Though, there are limited reports on this treatment including large number of Korean patients with IH covering a long-term powder and solution formulation period. Objective: We investigated the effectiveness and side effects of two different formulations of oral propranolol treatment in patients with IH at a Korean tertiary university hospital. Methods: From June 2011 to October 2019, 375 patients were treated with powder- or solution-type oral propranolol starting at 1 mg/kg/day and increasing up to 3 mg/kg/day. Drug effectiveness was evaluated on four scales through sequential photographs by two dermatologists. Side effects were recorded on a medical chart. Results: Overall, the mean improvement scale was 2.61±0.73 at 3 months after treatment initiation. The scale was higher for solution-type than for powder-type oral propranolol at the 3-month follow-up (2.71±0.79 vs. 2.54±0.67, p<0.05). The patients’ mean duration of treatment was 8.56±5.85 months, which was shorter for solution-type than for powder-type oral propranolol (6.0 vs. 10.69 months, p<0.05). Among the total number of patients, 22 reported mild side effects, including loose stools and noticeable sleep disturbance, and few serious side effects such as grunting, while two patients required medical intervention. Conclusion: The patients in our study were effectively treated for IH with oral propranolol without significant side effects and had a shorter treatment duration with solution-type oral propranolol than with powder-type oral propranolol. (Korean J Dermatol 2021;59(3):196∼205)